<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508937</url>
  </required_header>
  <id_info>
    <org_study_id>MM3717</org_study_id>
    <nct_id>NCT00508937</nct_id>
  </id_info>
  <brief_title>Dietary Protein and Insulin Sensitivity Study</brief_title>
  <official_title>The Effects of Increased Dietary Protein Intake on Insulin Sensitivity in Stable Weight Individuals, Independent of Dietary Content of Carbohydrate and Saturated Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Management Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the Dietary Protein and Insulin Sensitivity Study is to test the
      hypothesis that increased protein in a diet with reduced carbohydrate (35% energy) can
      ameliorate insulin resistance in the absence of weight loss, and that this effect is
      independent of saturated fat content. Moreover, we will test whether such diets result in
      beneficial changes in total LDL cholesterol, small, dense LDL, and HDL cholesterol that are
      also independent of saturated fat intake.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance is a major metabolic disturbance associated with excess adiposity that
      contributes to atherogenic dyslipidemia and predisposes to both cardiovascular disease and
      type 2 diabetes mellitus. The effects on insulin resistance of changes in dietary
      macronutrient composition in the absence of weight loss are poorly understood. To better
      understand these effects, we will study men and women with insulin resistance after 4 weeks
      on a basal diet (15% protein, 55% carbohydrate, 30% fat) and 4 weeks after random assignment
      to the basal diet or one of 4 diets with 35% carbohydrate and either 20% or 30% protein, and
      either 7% or 15% saturated fat. At the end of each dietary period (4 weeks and 8 weeks), we
      will draw a blood sample for detailed metabolic measurements and measure insulin sensitivity
      by the frequently sampled intravenous glucose tolerance test (FSIGT) method. In addition to
      insulin resistance, we will assess the effect of dietary composition on parameters of
      atherogenic dyslipidemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity by Frequently Sampled Intravenous Glucose Tolerance test</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL peak particle size</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL subclasses</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B</measure>
    <time_frame>4wks and 8wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A1</measure>
    <time_frame>4wks and 8wks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥ 27 and ≤ 40 kg/m2

          -  HOMA-IR ≥ 2.5

          -  Non-smoking

          -  Total cholesterol and LDL cholesterol &lt;95th percentile for sex and age

          -  Fasting triglycerides &lt; 500mg/dl

          -  Fasting blood sugar &lt; 126

          -  Urinary microalbumin &lt; 30 mg/L

          -  Normal thyroid stimulating hormone levels

          -  Hematocrit ≥ 36%

          -  Blood pressure &lt; 150/90

          -  At least 3 months of a weight-stable state (± 5 lbs) prior to the study. During the
             study, subjects will be required to maintain their body weight within ± 3% (up to a
             maximum change of 5 lbs) of their initial weight over the course of any consecutive
             two weeks after the second week of baseline diet or during the last week of each diet
             phase

        Exclusion Criteria:

          -  History of coronary heart disease, cerebrovascular disease, peripheral vascular
             disease, bleeding disorder, liver or renal disease, diabetes, lung disease, HIV, or
             cancer (other than skin cancer) in the last 5 years

          -  Use of drugs known to affect lipid metabolism or insulin resistance, hormones, or the
             blood thinning agent, warfarin

          -  Use of alcohol or dietary supplements during the study

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Krauss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital &amp; Research Center Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cholesterol Research Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.chori.org</url>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ronald M. Krauss, M.D.</name_title>
    <organization>Children's Hospital Oakland Research Institute</organization>
  </responsible_party>
  <keyword>Diet</keyword>
  <keyword>Protein</keyword>
  <keyword>Glucose</keyword>
  <keyword>Insulin</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>LDL subclasses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

